Ocugen Inc. Common Stock (OCGN)

FairStock Score: 14/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

As a value investor, I start with the numbers. Ocugen is a biotech with $1.5M revenue and a $24.9M net loss in fiscal Q2 2026, the quarter ended 2026-06-30. For FY2025, the year ended 2025-12-31, revenue was $4.4M and net loss $67.8M; FY2024 revenue was $4.1M and net loss $54.1M; FY2023 revenue was $6.0M and net loss $63.1M. So there is no earnings record, only losses, and the Lynch category is none because it lost money in each of the last four years. The business may have promising science, with OCU400 in Phase 3 for retinitis pigmentosa, but a moat is unproven. There is no commercial scale, pricing power, or durable competitive advantage I can underwrite. Financial health is poor: trailing free cash flow is -$61.0M, FCF yield -20.3%, Altman Z-Score -4.50, Piotroski 2/9, debt-to-equity 5.74, and ROE -660%. At the 2026-10-13 close of $0.88, market cap is $300.1M, and FairStock calculations show P/B of 69.50 and P/E of -3.40. Those are not value metrics; they reflect a speculative option on clinical success. The FairStock Score of 14/100 reinforces that. Growth? Revenue is barely moving and losses are large. In Graham terms, there is no margin of safety in current earnings or assets. In Buffett terms, I cannot judge the moat or normalized earning power. I would track the pipeline and cash burn, but today the stock is a binary bet, not a value investment.

In plain English: Ocugen is a small biotech company working on gene and cell therapies. It earns very little revenue and loses much more money than it brings in, so the business looks financially weak. At 88 cents a share, the stock looks expensive compared with its tiny sales and continuing losses.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer